Morning Report | U.S.-Iran coastal strikes, Hormuz risk premium hits duration
$ITA Mideast escalation bid $TLT 10Y 4.57% pressure $TLT FOMC minutes higher-for-longer tilt $FXI CPI miss, PPI post-2022 high $ITA Drone attrition risk bid
Market Pulse
U.S.-Iran War
3 events
U.S.-Iran conflict escalates via expanded coastal strikes and drone attrition, keeping Hormuz shipping disruption as the key driver of crude risk premium.
Latest Development
CENTCOM said U.S. forces struck about 90 Iranian coastal military targets, following a July 7 round of roughly 80 targets after Iran attacked three commercial vessels near the Strait of Hormuz.
Iran’s IRGC said it targeted U.S. facilities in Kuwait (Arifjan, Ali Al Salem) and Bahrain (Juffair, Sheikh Isa), extending retaliation risk to regional basing alongside maritime incidents.
A U.S. official said Iran has shot down around 30 MQ-9 Reaper drones since the war began, with limited near-term replacement capacity after the production line closed last year.
Market reaction
Crude repriced disruption risk: Brent settled up ~5.4% Wednesday and WTI up ~4.4%, then eased early Thursday with Brent around $77.73 (-0.3%) and WTI near $73.40 (-0.2%) after testing ~$80+ intraday.
Our view
Maintain a near-term long bias to front-month crude risk premium as repeated maritime incidents keep intermittent disruption odds elevated. The key monitor is whether attacks on commercial shipping persist and pull in broader retaliation against regional basing, which would likely sustain higher freight/insurance costs and volatility.
What could change our view
Sustained de-escalation that reduces maritime incidents and strips Hormuz risk premium.
Material damage to Gulf energy infrastructure triggers a sharper, disorderly supply shock.
Tickers: $ITA, $CL=F, $BZ=F
Macro & Policy Digest
Diesel shock intensifies after Russia export ban, pushing ULSD sharply higher and lifting cracks as distillate balances tighten into mid-summer.
Latest Development
Russia announced a diesel export ban; NYMEX ULSD settled +11.6% at $154.71/bbl as U.S. distillate stocks fell ~5.0M bbl to ~103.6M, exports averaged 1.7M bpd, diesel crack >$80/bbl, and wholesale hikes exceeded $0.40/gal.
Market reaction
NYMEX ULSD futures settled up 11.6% to $154.71/bbl, while the diesel crack spread surged above $80/bbl and wholesale diesel price hikes of over $0.40/gal were cited following the export ban.
Our view
The export ban prolongs global distillate tightness, keeping ULSD and diesel cracks elevated and supporting distillate-heavy refining earnings while raising near-term inflation sensitivity. Monitor whether the ban persists and whether weekly U.S. distillate stocks and export flows continue drawing, sustaining wholesale price pass-through.
What could change our view
Russia lifts export ban or shipments resume faster than expected.
U.S. distillate stocks stabilize and cracks retreat below recent highs.
Tickers: $HO=F
June FOMC minutes underscore higher-for-longer tilt as the Fed holds 3.50%–3.75% amid elevated inflation uncertainty and less forward guidance.
Latest Development
June minutes showed a unanimous hold at 3.50%–3.75%, upgraded year-end PCE inflation projection to 3.6%, and a dot-plot skew with 9 of 18 seeing at least one hike before end-2026.
Our view
Duration remains challenged as the Fed leans cautious on cuts and tolerates a higher-for-longer distribution under inflation uncertainty. Watch incoming inflation and energy-driven re-acceleration signals, as reduced forward guidance could amplify data-to-rates volatility and term-premium sensitivity.
What could change our view
Inflation cools decisively, pulling policy expectations toward earlier easing.
Inflation stays elevated with stable labor markets, forcing renewed firming.
Tickers: $TLT
Oil-driven inflation risk pushed Treasury yields higher with geopolitics in focus as 10Y neared 4.57% and duration faced renewed pressure.
Latest Development
U.S. yields rose with 10Y ~4.571% (+>4bp), 2Y ~4.206% (+>4bp), 30Y ~5.069% (+>2bp) as Brent +5.43% to $78.19 and WTI +4.37% to $73.52 after Trump said the Iran ceasefire was “over” and threatened additional strikes.
Market reaction
Treasury yields moved higher across the curve alongside a sharp oil rally, with 10Y near 4.57%, 2Y near 4.21%, and 30Y near 5.07% as Brent and WTI closed up over 5% and 4%, respectively.
Our view
Rates stay biased higher at the long end as oil-linked inflation risk keeps term premia elevated, keeping duration (TLT) under pressure. Watch whether crude strength persists and whether inflation expectations (breakevens) reprice further given geopolitics and the still-split June FOMC minutes.
What could change our view
Crude prices reverse sharply, easing near-term inflation and term-premia pressure.
Clear Fed pivot toward lower policy rate by year-end compresses yields.
Tickers: $TLT
China’s June inflation split—CPI undershot while PPI hit a post-2022 high—keeping the two-speed growth debate central for China and cyclicals.
Latest Development
June CPI rose 1.0% y/y versus 1.1% expected, with core CPI also 1.0%; June PPI rose 4.1% y/y (strongest since July 2022) but fell 0.3% m/m.
Our view
That investors keep a two-speed China framework: firmer producer prices support industrial commodities and materials sentiment, while soft CPI caps a broad rerating in China equities such as FXI. Monitor whether core CPI and m/m PPI momentum turn higher together, indicating demand-led pricing rather than margin pressure.
What could change our view
Core CPI re-accelerates, signaling stronger domestic demand and broader reflation.
PPI cools sharply or stays negative m/m, undermining commodity and cyclicals sentiment.
Tickers: $FXI
Company Events
Consumer earnings prints highlight a bifurcated demand backdrop, with U.S. softness at PepsiCo and guidance optimism at Levi failing to satisfy investors.
Latest Development
PepsiCo reported mixed Q2 results with North America volumes weak (beverages -4%, food flat) while international growth supported global volumes; organic revenue rose 2.4% and FY guidance was reiterated.
Levi Strauss beat fiscal Q2 expectations and raised full-year adjusted EPS to $1.46-$1.52 and sales growth to 7.0%-7.5%, with management citing growth split roughly half price and half units.
Market reaction
Levi shares fell more than 5% in extended trading despite the beat and raised guidance.
Our view
Earnings are reinforcing a market that is increasingly sensitive to underlying volume health and margin implications, not just headline beats or guidance lifts. Watch for evidence that U.S. demand stabilizes without heavier promotion, as that will drive whether staples defensiveness or discretionary resilience sets the tone.
What could change our view
North America volumes re-accelerate quickly without incremental price cuts or promotions.
Discretionary unit demand fades, making raised guidance vulnerable to resets.
Tickers: $PEP, $LEVI
AI trade mixes mega-cap infrastructure capex escalation with rising political spending to shape federal rules and potential state-law preemption.
Latest Development
Meta announced its first Canadian data center, a 1GW Alberta (Sturgeon County) build estimated at about $9B with a 2–3 year construction timeline and multi-party grid planning.
Two AI-focused PACs spent at least $44M through end-June backing 40 congressional candidates and say they have raised over $200M, as debate centers on federal guardrails and preempting state AI laws.
Our view
AI remains a capex-led buildout story with policy risk increasingly in the foreground, keeping META sensitivity anchored to capex/free-cash-flow trajectory and XLK exposure tied to regulatory direction. Monitor whether momentum builds for federal preemption of state AI laws versus a fragmented regime.
What could change our view
META capex trajectory shifts materially, changing free-cash-flow expectations.
Federal AI legislation moves decisively toward or away from state-law preemption.
Tickers: $META, $XLK
Biotech tape splits as AZN/IONS sell off on a Phase III miss while GLSI advances trial supply clearance and ALNY rallies on reduced threat.
Latest Development
AstraZeneca said Phase III Wainua in ATTR-CM missed its 140-week primary endpoint versus placebo on background therapy, though its existing approval for nerve damage remains unaffected; management cited a stabilizer-baseline subgroup nuance.
Greenwich LifeSciences said the EMA cleared use of its commercially manufactured GP2 lot in the Phase III FLAMINGO-01 breast cancer trial in Europe, with shipments under way; U.S. sites are already treating with the same lot.
Market reaction
Premarket, AZN fell ~8% (after down as much as ~9%), IONS fell ~12.5%, and ALNY rose ~16% as investors repriced ATTR-CM competitive dynamics.
Our view
Expect continued stock-specific dispersion, with clinical readouts and regulatory process milestones driving moves rather than broad biotech beta. Next key monitor is whether AZN/IONS can credibly frame path-forward via subgroup interpretation and program strategy, versus markets treating the miss as a durable de-risking for competitors.
What could change our view
AZN/IONS present a clearer efficacy signal that revives ATTR-CM label expectations.
Further trial or manufacturing execution setbacks undermine GLSI’s site expansion and enrollment pace.
Tickers: $AZN, $GLSI
Apple deepens Broadcom tie with a $30B+ multi-year U.S. chip supply and ASIC roadmap through 2031, boosting visibility for AVGO.
Latest Development
Apple and Broadcom signed long-term agreements expected to exceed $30B to supply 15B+ U.S.-made chips and develop custom ASIC silicon through 2031, alongside Broadcom’s $1.5B Fort Collins, Colorado expansion.
Market reaction
Broadcom shares rose about 5% Wednesday after the announcement.
Our view
We see the Apple agreements as supportive for Broadcom’s medium-term revenue visibility and customer stickiness, with incremental upside as custom ASIC content expands across product generations. Key watch items are disclosed timing of new U.S. capacity and any updates on scope or volume commitments in future filings.
What could change our view
Capacity ramp timing slips or volumes fall short of implied commitments.
Apple reduces custom ASIC reliance, limiting Broadcom’s multi-generation design win.
Tickers: $AVGO
Equinox Gold updates Q2 output and highlights Canadian ramp-up as investors head toward a July 22 shareholder vote on Orla deal issuance.
Latest Development
Equinox reported Q2 consolidated production of 176,836 oz, with Greenstone and Valentine contributing 97,273 oz and Canada output up 11% QoQ; shareholders vote July 22 on issuing up to 421,770,377 shares for the Orla stock-for-stock deal.
Our view
The story stays operations-driven near term, with Canadian ramp-up metrics doing more for EQX sentiment than the pending Orla consideration mechanics. Next key monitor is the July 20 proxy deadline and July 22 vote outcome, which will clarify deal execution risk and potential share overhang.
What could change our view
Shareholder vote fails or requires amended terms, extending deal uncertainty.
Greenstone or Valentine throughput/grade momentum slips, undermining 2H expectations.
Tickers: $EQX
Go deeper -
For intraday developments, follow our Midday posts.
For the close, the wrap, and next-day trade ideas, read the Evening Memo.
For deeper work, Forward Valuation covers multi-week single-name setups (paid subscribers only).
Deep Dive is where we publish our full thematic research for paid subscribers.
Informational only; not investment advice. Sources deemed reliable.